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2765thrombolysis in a developing nation. We found that
those patients who were randomized to receive RIC
upon arrival at the hospital and before thrombolytic
therapy experienced a signiﬁcant reduction in enzy-
matic MI size compared with the control group. The
size of this cardioprotective effect was comparable to
that observed in STEMI patients treated by PPCI, for
which studies have reported 25% to 30% reductions in
MI size as measured by myocardial single-photon
emission computed tomography and cardiac mag-
netic resonance imaging (3–5). The limitations of our
study include the following: 1) although tissue plas-
minogen activator (t-PA) is the most commonly used
thrombolytic agent in developed countries, strepto-
kinase (which costs 10-fold less than t-PA) continues
to be used in developing nations; and 2) conducting a
randomized control trial in a developing nation with
very limited resources was challenging and explains
in part why we were only able to obtain data on
enzymatic MI size.
In conclusion, we have shown that RIC reduced MI
size in STEMI patients treated with thrombolysis,
making this noninvasive, easily applied, low-cost
therapy an attractive option in developing nations
where health care resources are limited and current
therapy is not optimal.
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178–88.Are Phytosterols
Responsible for
the Low-Density
Lipoprotein–Lowering
Effects of Tree Nuts?
A Systematic Review and Meta-AnalysisIntake of tree nuts is associated with a lower risk of
cardiovascular events in prospective cohorts and
the PREDIMED (Prevención con Dieta Mediterránea)
trial (1). Previous meta-analyses indicated that tree
nut intake lowered low-density lipoprotein (LDL)
cholesterol (2,3). However, few trials (#13 studies)
were included in these meta-analyses; pooled effects
were not standardized to a common dose, which
prevented conclusions about the magnitude of effects
for a given intake of nuts, and speciﬁc constituents in
tree nuts were not examined for their contributions
to this LDL-lowering effect. Tree nuts are rich
in phytosterols that displace cholesterol from intes-
tinal micelles and reduce the pool of absorbable
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2766cholesterol. Phytosterols also exhibit LDL-lowering
effects in intact foods (4).
To investigate the role of phytosterols in the
LDL-lowering effect of tree nuts, we conducted a
systematic review and meta-analysis of controlled
interventional trials. We included trials that provided
nuts or dietary advice and that examined LDL
cholesterol in adults (age $18 years) who were free of
coronary heart disease or stroke.
Two investigators (M.F., K.L.) screened potentially
eligible PubMed articles, adjudicated inclusion de-
cisions, and extracted data. We calculated mean dif-
ferences between tree nut intervention and control
arms that were dose-standardized to one 1-oz (28.4 g)
serving/day, using inverse variance ﬁxed-effects
meta-analysis. Phytosterol dose was determined by
multiplying the daily nut intake by the phytosterol
content of the speciﬁc nut types supplied (4), with
and without adjustment for the overall dose of nuts.
Meta-regression was used to evaluate the association
of phytosterol intake with LDL cholesterol.
Of 1,301 potentially eligible articles, 61 trials
met eligibility criteria (42 randomized, 18 nonran-
domized), with a total of 2,582 unique participants.
Interventions ranged from 3 to 26 weeks, with nut and
phytosterol doses ranging from 0.2 to 3.5 servings and
4.8 to 279 mg/day, respectively. Across the 61 trials,
the median baseline LDL cholesterol concentration
was 131 mg/dl (range: 73 to 162 mg/dl). All of the trials
directly provided nuts, rather than relying only onions of Phytosterol Intake From Nuts and Mean Difference in LDL
Randomized controlled trial Non-ra
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and mean difference in LDL (standardized to 1 serving/day). Phytosterol-LDL
by multiplying the daily nut intake dose for a given nut type from each trial b
were excluded. LDL ¼ low-density lipoprotein.dietary advice. Fourteen trials included advice to
maintain isocaloric balance; in the remaining 47 trials,
participants were provided nuts on top of a common
background diet. Compliance was generally assessed
using self-reported dietary recalls or direct supervi-
sion of nut consumption. For meta-regression, trials
of mixed nuts (in which the phytosterol content of
speciﬁc nut types could not be ascertained) were
excluded.
Compared with control groups, each daily serving
of tree nuts lowered LDL cholesterol (–4.8 mg/dl; 95%
conﬁdence interval: –5.5 to –4.2). Total phytosterol
intake from nuts was correlated with nut dose
(r ¼ 0.84). In pooled analyses, total phytosterol dose
from nuts was inversely correlated with a reduction
in LDL (r ¼ –0.60) (Figure 1A). However, this associa-
tion was not independent of total nut dose: after
standardization of nut dose, phytosterol content was
no longer independently associated with LDL
(r ¼ –0.01; p > 0.05) (Figure 1B).
Potential limitations should be considered.
Compliance was often assessed by self-report, and
low compliance could cause underestimation of ef-
fects. Some trials were nonrandomized; however,
similar ﬁndings were seen in randomized trials (data
not shown). The relative variation in phytosterol
dose, accounting for total nut dose, might be too
small to be clinically meaningful.
In conclusion, our analysis demonstrates that the
dose of phytosterol intake from tree nuts is associatedndomized trial
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lation of phytosterol intake (standardized to 1 serving/day [28.4 g] of
associations were modeled using meta-regression. Total phytosterol
y the phytosterol content of each nut type, given in Phillips et al. (4).
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2767with the LDL-lowering effect, but that this relation-
ship is driven by the total daily dose of nuts, rather
than by differences in phytosterol content between
types of nuts.*Liana C. Del Gobbo, PhD
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Mitral Regurgitation?I read with great interest the article by Grayburn et al.
(1), which deﬁned “severe” secondary mitral regur-
gitation (MR). The investigators did a great job of
explaining the mechanism and application of new
guidelines in the evaluation of MR. The investi-
gators proposed that classiﬁcation of a patient with
severe secondary MR should be deferred until
guideline-directed medical therapy or interventions
are optimized.
Current guidelines for valvular heart disease deﬁne
the class of valvular heart disease by echocardio-
graphic data and symptoms, asymptomatic severe MR(stage C), and symptomatic severe MR (stage D) (2).
However, the severity of MR is primarily based on
the echocardiographic ﬁndings, including color
Doppler, vena contracta, effective regurgitant oriﬁce,
and regurgitant volume and/or fraction. It is well
known that the severity of MR is dependent on the
loading conditions (blood pressure and heart rate),
and that there may be disparities among various pa-
rameters for the assessment of severity. The echo-
cardiologist reading the study may not have any
knowledge about the optimization of the medical
therapy, and may ﬁnd it difﬁcult not to describe a
patient with severe MR if the patient meets the
echocardiographic diagnostic criteria for severe MR.
It seems more logical to say that the decision to
recommend surgical or other invasive procedures
should be deferred until the guideline-directed ther-
apy has been optimized and the severity of MR sub-
sequently reassessed. However, more research is
needed in this area to further deﬁne the duration of
optimal therapy.*Gyanendra K. Sharma, MD
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Mitral Regurgitation?As stated in our review article, functional mitral
regurgitation (MR) is notoriously dynamic and may
change in severity depending on loading conditions
(1). Dr. Sharma correctly points out that echocardi-
ographers may be unaware of whether a given patient
is appropriately treated or not, and therefore, they
must base severity on the echocardiographic ﬁndings
alone. We agree with Dr. Sharma that “the decision to
recommend surgical or other invasive procedures
should be deferred until the guideline-directed
